150 mg daily for a month then 300 mg daily for the rest of the study (5 months)

Musculoskeletal Degeneration

Inflammation

Hyperuricemia

Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.
Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant.

Allopurinol Pill

Instituto Nacional de Cardiología

National Institute of Cardiology Mexico

Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms

Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept

To measure changes in proinflammatory cytokines (Interleukin 1ß (IL-1ß))

To measure changes in proinflammatory cytokines (Tumor Necrosis Factor)

To measure changes in proinflammatory cytokines (Interleukin 6 (IL-6))

To measure changes in proinflammatory cytokines (Interferon-γ)

To measure changes in proinflammatory cytokines (Interleukin 18 (IL-18))

To measure changes in proinflammatory cytokines (Interleukin 17 (IL-17))

To measure changes in chemokines (Interleukin 8 (IL-8))

To measure changes in chemokines (monocyte chemoattractant protein 1 (MCP-1))

To measure changes in microRNAs (miR) (miR-155)

To measure changes in the percentage of Cluster of Differentiation 4 cells that lack the expression of Cluster of Differentiation 28 (CD4+CD28null)

Presence of the ultrasonographic elemental lesions caused by monosodium urate crystals: (Double contour sign is a hyperechoic abnormal band over the superficial margin of articular hyaline cartilage, independent from insonation angle which can be regular or irregular, continuous or intermittent and that distinguishes itself from the cartilage interphase sign)

Presence of the ultrasonographic elemental lesions caused by monosodium urate crystals: (Tophi are described, independent of location, as an heterogenous, circumscript aggregate, hyper- and/or hypoechoic, which can be surrounded by a small anechoic halo and can have a posterior acoustic shadow)

Presence of the ultrasonographic elemental lesions caused by monosodium urate crystals: (Aggregates are described, independent of location, as heterogenous hyperechoic foci which maintain a high degree of reflectivity even when gain is reduced to the minimum or when the insonation angle is changed, also they can sometimes create a posterior acoustic shadow)

Presence of the ultrasonographic elemental lesions caused by monosodium urate crystals: (Erosions are described as a discontinuation of the bone surface, seen in two perpendicular planes)

Luis M Amezcua-Guerra

Head of Immunology Department, Principal Investigator

Instituto Nacional de Cardiologia Ignacio Chavez

Instituto Nacional de Rehabilitacion

Personalized diet added with quinoa and flaxseed

Personalized diet without dietary supplement

Metabolic Syndrome

Nutritional and Metabolic Diseases

Quinoa

Flaxseed

personalized diet added with quinoa and flaxseed

Quinoa and Flaxseed

Epidemiología y determinantes sociales asociados a la obesidad y la diabetes tipo 2 en México

NORMA Oficial Mexicana NOM-037-SSA2-2012, Para la prevención, tratamiento y control de las dislipidemias.

Diferencias entre la prevalencia de obesidad y exceso de peso estimadas con datos declarados o por medición directa en adultos de la Comunidad Valenciana

Consumer Acceptability of Muffins with Flaxseed (Linum usitatissimum)

Flavonoids and other phenolic compounds in Andean indigenous grains: Quinoa (Chenopodium quinoa), kañiwa (Chenopodium pallidicaule) and kiwicha (Amaranthus caudatus)

Nutraceuticals and Functional Foods in Health Promotion and Disease Risk Reduction

Inhibition of reverse transcriptases by flavonoids

Utilidad de la Prueba de Micronúcleos y Anormalidades Nucleares en Células Exfoliadas de Mucosa Oral en la Evaluación de Daño Genotóxico y Citotóxico

Procedimientos básicos de la prueba de micronúcleos y anormalidades nucleares en células exfoliadas de mucosa oral

Una nueva definición mundial del síndrome metabólico propuesta por la Federación Internacional de Diabetes: fundamento y resultados

Hospital Civil de Guadalajara "Fray Antonio Alcalde"

Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara

Efect of Quinoa and Flaxseed in Cititoxicity and Glicemic Control in Metabolic Syndrome Patients

Evaluation of the Citotoxicity and Clicemic Control of Subject With Metabolic Syndrome Managed With Conventional Nutritional Tratment More Quinoa, Flaxseed or Borh Versus Conventional Nutrition

The number of micronuclei will be evaluated at baseline at 12 weeks and 24 weeks with Schmidt technique by Giemsa/wright and the entered values reflect the number of micronuclei at week 24

The fasting glucose levels will be evaluated at baseline, at 12 weeks and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at 24 weeks

Glycosylated hemoglobin will be evaluated at baseline, at 12 weeks and 24 weeks by high-pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at 24 weeks

The body weight will be measured at baseline, at 12 weeks and 24 weeks with a bioimpedance balance and the entered values reflect the body weight at 24 weeks

Body Mass Index will be calculated at baseline, 12 weeks and 24 weeks with the Quetelet index formula and the entered values reflect the body mass index at 24 weeks

Waist circumference will be evaluated at baseline and at 24 weeks with a flexible tape

Total cholesterol levels will be evaluated at baseline and 24 weeks by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at 24 weeks

Triglycerides levels will be evaluated at baseline and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at 24 weeks

c-HDL levels will be evaluated at baseline and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at 24 weeks

c-LDL levels will be evaluated at baseline and 24 weeks with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at 24 weeks

Blood pressure will be measured at baseline and 24 weeks with a digital sphygmomanometer and the entered values reflect the blood pressure at 24 weeks

El uso de los datos es exclusivo de los investigadores involucrados en el estudio sin la devulgacion de los mismos a terceros externos al equipo de trabajo

Ana Lilia Fletes Rayas

PROFESSOR ASSOCIATE TYPE A

University of Guadalajara

Hospital Civil de Guadalajara

An open clinical trial with randomization plus control group

Overweight

Obesity

Dyslipidemia

Hyperlipidemia

Diabetes

Prediabetes

Dysglycemia

Gout

Hypertension

Coronary Heart Disease

Cardiovascular Disease

The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital

Meta-analyses of Total and Individual Fructose-containing Sugars and Incident Cardiometabolic Disease

The Relation of Total and Individual Fructose-containing Sugars With Incident Cardiometabolic Diseases: A Series of Systematic Reviews and Meta-analyses of Prospective Observational Studies

Risk ratios for incident Overweight and obesity by total fructose-containing sugar exposure

Risk ratios for incident diabetes and metabolic syndrome by total fructose-containing sugar exposure

Risk ratios for incident hypertension by total fructose-containing sugar exposure

gout/nikotīns

Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms

Efect of Quinoa and Flaxseed in Cititoxicity and Glicemic Control in Metabolic Syndrome Patients

Meta-analyses of Total and Individual Fructose-containing Sugars and Incident Cardiometabolic Disease

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne